Polymeric contrast agents for use in medical imaging
OwnerEgidijus Uzgiris, Mohan Amaratunga +3inventors
InventorsEgidijus Uzgiris, Mohan Amaratunga, Brian Grimmond, Daniel Meyer, Joanne Smith
Life of this patent
Estimating the term…
Abstract
A contrast agent comprising a polypeptide is provided. The polypeptide contains lysine residues and optionally, one or more types of amino acid residues selected from the group consisting of glutamic acid residues and aspartic acid residues, wherein the lysine residues are substituted with a group derived from a steric hindrance molecule; and an image producing entity is present in a range between about 100 units and about 2000 units. Methods for administering the aforementioned contrast agent are also provided.
Claims36
A contrast agent comprising a polypeptide containing lysine residues and optionally, one or more types of amino acid residues selected from the group consisting of glutamic acid residues and aspartic acid residues, wherein the lysine residues are substituted with a group derived from a steric hindrance molecule;
- and
- an image producing entity present in a range between about 100 ions and about 2000 ions.
A contrast agent comprising a polylysine, wherein the lysine residues are substituted with a group derived from a steric hindrance molecule;
- and
- an image producing entity of gadolinium ions present in a range between about 100 ions and about 2000 ions.
A method comprising
- a) administering a contrast agent to a subject wherein the contrast agent comprises a polypeptide containing lysine residues and optionally, one or more types of amino acid residues selected from the group consisting of glutamic acid residues and aspartic acid residues, wherein the lysine residues are substituted with a group derived from a steric hindrance molecule and an image producing entity present in a range between about 100 ions and about 2000 ions;
- and
- b) imaging the subject via magnetic resonance imaging.
A method of pre-targeting tissue comprising:
- a) injecting an antibody labeled with a receptor molecule into a subject;
- b) injecting a contrast agent to the subject wherein the contrast agent comprises a polypeptide containing lysine residues and optionally, one or more types of amino acid residues selected from the group consisting of glutamic acid residues and aspartic acid residues, wherein the lysine residues are substituted with a group derived from a steric hindrance molecule, an image producing entity present in a range between about 100 ions and about 2000 ions, and a targeting ligand wherein the targeting ligand binds to the receptor molecule;
- and
- c) imaging the subject via magnetic resonance imaging.
Dependencies are inferred from the claim text.